Radiation Dose Management Market is expected to reach US$ 646.87 Million by 2028

Radiation Dose Management Software Segment to Lead Global Radiation Dose Management Market during 2021–2028

According to our new research study on “Radiation Dose Management Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by service/ software, medium, and end user,” the market is expected to grow from US$ 270.32 million in 2021 to US$ 646.87 million by 2028; it is estimated to grow at a CAGR of 13.3% during 2021–2028. Factors driving the growth of the market are the growing concerns related to radiation exposure and rising cases of cancer demanding radiation therapy.

Based on service/software, the radiation dose management market is segmented into radiation dose management services and radiation dose management software. The radiation dose management software segment held the largest share of the market in 2021 and is anticipated to register the highest CAGR in the market during the forecast period. The use of radiation dose management software can improve the collection, analysis, and reporting of radiation dose data compared to current manual or semi-automated methods. Radiation dose management software can also alert healthcare professionals to radiation exposure when DRLs are consistently exceeded. Some technologies can help facilitate the management of protocols, contrast agent and staff dose, and image quality.

The global economy was severely affected due to the COVID-19 cases in all the regions. The rising occurrence rate of coronavirus results had increased stress on the region's healthcare system. During the COVID-19 pandemic, outpatient appointments were avoided as far as possible. This increases the risk of infection for both the patient and the medical staff running the clinic. The COVID-19 pandemic is perplexing healthcare institutions in the region with unprecedented operational and clinical challenges. On March 11, 2020, the American College of Radiology (ACR) had recommended that CT should not be used for the purpose of screening or diagnosis of COVID-19 and that its use should be reserved for specific indications in hospitalized and symptomatic subjects. The COVID-19 pandemic had severely impacted radiology services across Europe. The Board of the European Cancer Organization paid particular attention to the increasing impact of COVID-19 on the treatment of cancer patients and the effects of the current situation on the functioning of European science, education of health professionals, and patient associations.

Responses to the COVID-19 pandemic have varied between and within countries across Europe. Screenings for breast cancer screening was the hardest hit, however, screenings for non-critical diseases and elective radiology were also discontinued. Inpatient radiology examinations also declined as admissions declined. Hospitals are assigning beds to COVID-19 patients, and others have avoided hospitals as much as possible. There was a perceived workload increase in general x-ray and computed tomography imaging procedures in the Middle East & Africa region because they were the key modalities for the initial and follow-up investigations of COVID-19. Hence, the COVID 19 had somewhat negative impact on the radiation dose management market before the introduction of COVID-19 vaccine.

FUJIFILM Holdings Corporation; Bayer AG; Bracco Imaging S.p.A; GE Healthcare; Koninklijke Philips N.V.; Medsquare; Novarad Corporation; QAELUM INC.; Sectra AB; and PACSHealth, LLC are among the leading companies operating in the radiation dose management market.

Radiation Dose Management Market, by Region, 2021 (%)